The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials
Conghui Jin, Xunlei Zhang, Kuiling Zhao, Jun Xu, Min Zhao, Xiaohong Xu Department of Medical Oncology, Nantong Tumor Hospital, Nantong, People’s Republic of China Background: Nivolumab has become a therapeutic regimen for the treatment of patients with advanced melanoma. The goal of this...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-03-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/the-efficacy-and-safety-of-nivolumab-in-the-treatment-of-advanced-mela-peer-reviewed-article-OTT |
id |
doaj-efe863576c37429d9c86d99f92e8c15a |
---|---|
record_format |
Article |
spelling |
doaj-efe863576c37429d9c86d99f92e8c15a2020-11-24T20:56:22ZengDove Medical PressOncoTargets and Therapy1178-69302016-03-012016Issue 11571157826034The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trialsJin CHZhang XLZhao KLXu JZhao MXu XHConghui Jin, Xunlei Zhang, Kuiling Zhao, Jun Xu, Min Zhao, Xiaohong Xu Department of Medical Oncology, Nantong Tumor Hospital, Nantong, People’s Republic of China Background: Nivolumab has become a therapeutic regimen for the treatment of patients with advanced melanoma. The goal of this study was to assess the efficacy and safety of nivolumab in patients with advanced melanoma.Methods: A systematic search from January 2008 to August 2015 with “nivolumab” and “advanced melanoma” as search terms was performed for possible clinical trials. According to the hazard ratio and the 95% confidence interval (CI) for progression-free survival (PFS), rates of objective response, complete response, partial response, rates of toxic effects, and the efficacy and safety of nivolumab were assessed. Using the software Review Manager (version 5.3) a meta-analysis was performed.Results: There were four trials with 1,910 patients included. Based on the four trials, the pooled hazard ratio of PFS was 0.53 (95% CI, 0.43–0.66; P<0.001). The pooled risk ratio for the objective response rate, complete response, and partial response was 2.98% (95% CI, 2.38%–3.73%; P<0.001), 3.71% (95% CI, 2.67%–5.14%; P<0.001), and 2.51% (95% CI, 2.12%–2.99%; P<0.001), respectively. Nivolumab plus ipilimumab therapy significantly increased the risk of grade 3/4 rash and fatigue.Conclusion: Nivolumab-based therapy prolonged PFS in treatment of advanced melanoma, with less adverse effects. Nivolumab appears to be a favorable treatment option as a novel, targeted anticancer agent, for patients with advanced melanoma. Keywords: nivolumab, advanced melanoma, meta-analysishttps://www.dovepress.com/the-efficacy-and-safety-of-nivolumab-in-the-treatment-of-advanced-mela-peer-reviewed-article-OTTnivolumabadvanced melanomaMeta-analysis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jin CH Zhang XL Zhao KL Xu J Zhao M Xu XH |
spellingShingle |
Jin CH Zhang XL Zhao KL Xu J Zhao M Xu XH The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials OncoTargets and Therapy nivolumab advanced melanoma Meta-analysis |
author_facet |
Jin CH Zhang XL Zhao KL Xu J Zhao M Xu XH |
author_sort |
Jin CH |
title |
The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials |
title_short |
The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials |
title_full |
The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials |
title_fullStr |
The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials |
title_full_unstemmed |
The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials |
title_sort |
efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials |
publisher |
Dove Medical Press |
series |
OncoTargets and Therapy |
issn |
1178-6930 |
publishDate |
2016-03-01 |
description |
Conghui Jin, Xunlei Zhang, Kuiling Zhao, Jun Xu, Min Zhao, Xiaohong Xu Department of Medical Oncology, Nantong Tumor Hospital, Nantong, People’s Republic of China Background: Nivolumab has become a therapeutic regimen for the treatment of patients with advanced melanoma. The goal of this study was to assess the efficacy and safety of nivolumab in patients with advanced melanoma.Methods: A systematic search from January 2008 to August 2015 with “nivolumab” and “advanced melanoma” as search terms was performed for possible clinical trials. According to the hazard ratio and the 95% confidence interval (CI) for progression-free survival (PFS), rates of objective response, complete response, partial response, rates of toxic effects, and the efficacy and safety of nivolumab were assessed. Using the software Review Manager (version 5.3) a meta-analysis was performed.Results: There were four trials with 1,910 patients included. Based on the four trials, the pooled hazard ratio of PFS was 0.53 (95% CI, 0.43–0.66; P<0.001). The pooled risk ratio for the objective response rate, complete response, and partial response was 2.98% (95% CI, 2.38%–3.73%; P<0.001), 3.71% (95% CI, 2.67%–5.14%; P<0.001), and 2.51% (95% CI, 2.12%–2.99%; P<0.001), respectively. Nivolumab plus ipilimumab therapy significantly increased the risk of grade 3/4 rash and fatigue.Conclusion: Nivolumab-based therapy prolonged PFS in treatment of advanced melanoma, with less adverse effects. Nivolumab appears to be a favorable treatment option as a novel, targeted anticancer agent, for patients with advanced melanoma. Keywords: nivolumab, advanced melanoma, meta-analysis |
topic |
nivolumab advanced melanoma Meta-analysis |
url |
https://www.dovepress.com/the-efficacy-and-safety-of-nivolumab-in-the-treatment-of-advanced-mela-peer-reviewed-article-OTT |
work_keys_str_mv |
AT jinch theefficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT zhangxl theefficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT zhaokl theefficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT xuj theefficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT zhaom theefficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT xuxh theefficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT jinch efficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT zhangxl efficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT zhaokl efficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT xuj efficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT zhaom efficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials AT xuxh efficacyandsafetyofnivolumabinthetreatmentofadvancedmelanomaametaanalysisofclinicaltrials |
_version_ |
1716789947649753088 |